Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Paradigm Biopharmaceuticals ( (AU:PAR) ).
Paradigm Biopharmaceuticals Limited announced the issuance of 5,000,000 unquoted convertible notes as part of a previously disclosed transaction. This move is part of the company’s strategic financial operations, potentially impacting its capital structure and providing additional resources for its ongoing projects.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited operates in the biopharmaceutical industry, focusing on developing and commercializing therapies for treating inflammation-related diseases. The company is known for its innovative approaches and commitment to addressing unmet medical needs.
YTD Price Performance: -9.33%
Average Trading Volume: 1,119,134
Technical Sentiment Signal: Sell
Current Market Cap: A$145.7M
For a thorough assessment of PAR stock, go to TipRanks’ Stock Analysis page.